PDL BIOPHARMA, INC.

HUZAF

Pharmaceutical preparations for the treatment of auto-immune, inflammatory and allergic diseases; pharmaceutical preparations for the treatment of oncology/hematological malignancies;

NUVION

Pharmaceutical product for the diagnosis, treatment and prevention of transplant rejection, graft vs host disease, and autoimmune diseases including, multiple sclerosis, Crohn's disease, psoriasis, systemic lupus erythematosus, and rheumatoid arthritis;

PDL

Pharmaceutical preparations, namely, those for the treatment, prevention and diagnosis of allergies, autoimmune deficiencies, cardiovascular, inflammatory, ophthalmic, oncological, and organ transplant-related conditions and diseases;

PDL

Printed educational materials, namely, pamphlets, booklets and brochures concerning the treatment, prevention and diagnosis of diseases, including allergies, autoimmune deficiencies, cardiovascular, inflammatory, ophthalmic, oncological, and organ transplant-related conditions and diseases;

PDL

PROTEIN DESIGN LABS;Financing of loans, venture capital financing, financing related to intellectual property portfolios; financing of pharmaceutical, drug, and medical device development; equity capital investment;

PDL

Licensing of intellectual property in the field of pharmaceuticals and drug treatment;

PDL

The mark consists of a green horizontal line, with the left side connected to a green vertical line. Inside the connecting lines in capital blue letters is PDL.;Financing of loans, venture capital financing, financing related to intellectual property portfolios; financing of pharmaceutical, drug, and medical device development; equity capital investment;The color(s) green and blue is/are claimed as a feature of the mark.;